Patents by Inventor Philippe Gabant

Philippe Gabant has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11932672
    Abstract: Some embodiments relate to a method for producing a product of interest with a microbial host using an auto-replicative extra-chromosomal nucleic acid molecule comprising a first nucleic acid sequence whose genetic activity confers an advantage to the host, optionally wherein the genetic activity of said first nucleic acid molecule is controlled.
    Type: Grant
    Filed: December 19, 2018
    Date of Patent: March 19, 2024
    Assignees: Syngulon S.A., Université Libre de Bruxelles
    Inventors: Philippe Gabant, Mohamed El Bakkoury, Laurence Van Melderen
  • Publication number: 20230414707
    Abstract: Methods of producing a secreted antimicrobial peptide in a microbial community are described. The method can comprise administering a nucleic acid to at least one of the desired microbial organisms of the microbial community in situ. The genetically modified desired microbial organism secretes the antimicrobial peptide. Microbial communities are described.
    Type: Application
    Filed: November 5, 2021
    Publication date: December 28, 2023
    Inventor: Philippe Gabant
  • Publication number: 20230416797
    Abstract: Methods of modulating the half-life of an antimicrobial peptide are described. The method may include administering an antimicrobial peptide to an environment where the antimicrobial peptide remains active until a specified endpoint, and on or after the specified endpoint, digesting the antimicrobial peptide with a protease to thereby inactivate the antimicrobial peptide and modulate its half-life. Compositions and kits for modulating the half-life of an antimicrobial peptide are also described.
    Type: Application
    Filed: November 5, 2021
    Publication date: December 28, 2023
    Inventor: Philippe Gabant
  • Publication number: 20230279461
    Abstract: Methods and compositions for making bacteriocins are described in some embodiments herein. In some embodiments, pro-polypeptide comprising the bacteriocins in the desired ratios in cis, and separated by cleavage sited can be produced by a microbial cell comprising a nucleic acid encoding the pro-polypeptide. In some embodiments microfluidic devices and methods for making specified mixtures of antimicrobial peptides and/or bacteriocins are described.
    Type: Application
    Filed: November 3, 2022
    Publication date: September 7, 2023
    Inventor: Philippe Gabant
  • Publication number: 20230193191
    Abstract: It can be useful to regulate the growth of microbial cells. Some embodiments herein provide genetically engineered microbial cells that can produce bacteriocins to control the growth of microbial cells. In some embodiments, microbial cells are contained within a desired environment. In some embodiments, contaminating microbial cells are neutralized. In some embodiments, a first microbial cell type regulates the growth of a second microbial cell type so as to maintain a desired ratio of the two cell types.
    Type: Application
    Filed: August 26, 2022
    Publication date: June 22, 2023
    Inventor: Philippe Gabant
  • Patent number: 11492651
    Abstract: Methods and compositions for making bacteriocins are described in some embodiments herein. In some embodiments, pro-polypeptide comprising the bacteriocins in the desired ratios in cis, and separated by cleavage sited can be produced by a microbial cell comprising a nucleic acid encoding the pro-polypeptide. In some embodiments microfluidic devices and methods for making specified mixtures of antimicrobial peptides and/or bacteriocins are described.
    Type: Grant
    Filed: August 30, 2018
    Date of Patent: November 8, 2022
    Assignee: Syngulon SA
    Inventor: Philippe Gabant
  • Patent number: 11427800
    Abstract: It can be useful to regulate the growth of microbial cells. Some embodiments herein provide genetically engineered microbial cells that can produce bacteriocins to control the growth of microbial cells. In some embodiments, microbial cells are contained within a desired environment. In some embodiments, contaminating microbial cells are neutralized. In some embodiments, a first microbial cell type regulates the growth of a second microbial cell type so as to maintain a desired ratio of the two cell types.
    Type: Grant
    Filed: December 20, 2018
    Date of Patent: August 30, 2022
    Assignee: Syngulon SA
    Inventor: Philippe Gabant
  • Publication number: 20210238645
    Abstract: Embodiments herein relate to methods, systems and kits for engineering antimicrobial peptides such as bacteriocins, for example to have a desired range of activity in a desired range of culture conditions. The antimicrobial peptides may be engineered to have a particular activity for a particular culture, environmental conditions or a range of conditions. Some embodiments include screening an antimicrobial peptides or several candidate antimicrobial peptides for a desired activity. Some embodiments include an iterative process for engineering antimicrobial peptides such as bacteriocins. In some embodiments, the process is performed by automated machine learning.
    Type: Application
    Filed: June 5, 2019
    Publication date: August 5, 2021
    Inventor: Philippe Gabant
  • Publication number: 20210070812
    Abstract: Some embodiments relate to a method for producing a product of interest with a microbial host using an auto-replicative extra-chromosomal nucleic acid molecule comprising a first nucleic acid sequence whose genetic activity confers an advantage to the host, optionally wherein the genetic activity of said first nucleic acid molecule is controlled.
    Type: Application
    Filed: December 19, 2018
    Publication date: March 11, 2021
    Inventors: Philippe Gabant, Mohamed El Bakkoury, Laurence Van Melderen
  • Publication number: 20200263221
    Abstract: Methods and compositions for making bacteriocins are described in some embodiments herein. In some embodiments, pro-polypeptide comprising the bacteriocins in the desired ratios in cis, and separated by cleavage sited can be produced by a microbial cell comprising a nucleic acid encoding the pro-polypeptide. In some embodiments microfluidic devices and methods for making specified mixtures of antimicrobial peptides and/or bacteriocins are described.
    Type: Application
    Filed: August 30, 2018
    Publication date: August 20, 2020
    Inventor: Philippe Gabant
  • Publication number: 20190191709
    Abstract: It can be useful to regulate the growth of microbial cells. Some embodiments herein provide genetically engineered microbial cells that can produce bacteriocins to control the growth of microbial cells. In some embodiments, microbial cells are contained within a desired environment. In some embodiments, contaminating microbial cells are neutralized. In some embodiments, a first microbial cell type regulates the growth of a second microbial cell type so as to maintain a desired ratio of the two cell types.
    Type: Application
    Filed: December 20, 2018
    Publication date: June 27, 2019
    Inventor: Philippe Gabant
  • Patent number: 10188114
    Abstract: It can be useful to regulate the growth of microbial cells. Some embodiments herein provide genetically engineered microbial cells that can produce bacteriocins to control the growth of microbial cells. In some embodiments, microbial cells are contained within a desired environment. In some embodiments, contaminating microbial cells are neutralized. In some embodiments, a first microbial cell type regulates the growth of a second microbial cell type so as to maintain a desired ratio of the two cell types.
    Type: Grant
    Filed: March 31, 2016
    Date of Patent: January 29, 2019
    Assignee: SYNGULON SA
    Inventor: Philippe Gabant
  • Publication number: 20160213005
    Abstract: It can be useful to regulate the growth of microbial cells. Some embodiments herein provide genetically engineered microbial cells that can produce bacteriocins to control the growth of microbial cells. In some embodiments, microbial cells are contained within a desired environment. In some embodiments, contaminating microbial cells are neutralized. In some embodiments, a first microbial cell type regulates the growth of a second microbial cell type so as to maintain a desired ratio of the two cell types.
    Type: Application
    Filed: March 31, 2016
    Publication date: July 28, 2016
    Inventor: Philippe Gabant
  • Patent number: 9333227
    Abstract: It can be useful to regulate the growth of microbial cells. Some embodiments herein provide genetically engineered microbial cells that can produce bacteriocins to control the growth of microbial cells. In some embodiments, microbial cells are contained within a desired environment. In some embodiments, contaminating microbial cells are neutralized. In some embodiments, a first microbial cell type regulates the growth of a second microbial cell type so as to maintain a desired ratio of the two cell types.
    Type: Grant
    Filed: August 14, 2014
    Date of Patent: May 10, 2016
    Assignee: Syngulon SA.
    Inventor: Philippe Gabant
  • Patent number: 9309518
    Abstract: The present invention is related to integrated method and tools to construct recombinant DNA molecules (to be used as DNA vaccine or gene therapy) without requiring the use of antibiotic(s) resistance gene(s) and without requiring the addition of one or more antibiotic(s) to the culture medium of cells submitted to this recombinant DNA method. The present invention allows to obtain the selection of recombinant host cell(s) transformed by a (exogenous) nucleic acid sequence of interest (extra-chromosomal vector containing the insert) and simultaneously stabilization (stable inheritance) of this (exogenous) nucleic acid sequence of interest into the transformed host cell(s) descendants (maintenance of the nucleic acid sequence of interest in the host cells population).
    Type: Grant
    Filed: October 25, 2012
    Date of Patent: April 12, 2016
    Assignee: Universite Libre de Bruxelles
    Inventors: Cédric Szpirer, Michel C. Milinkovitch, Philippe Gabant
  • Publication number: 20150050253
    Abstract: It can be useful to regulate the growth of microbial cells. Some embodiments herein provide genetically engineered microbial cells that can produce bacteriocins to control the growth of microbial cells. In some embodiments, microbial cells are contained within a desired environment. In some embodiments, contaminating microbial cells are neutralized. In some embodiments, a first microbial cell type regulates the growth of a second microbial cell type so as to maintain a desired ratio of the two cell types.
    Type: Application
    Filed: August 14, 2014
    Publication date: February 19, 2015
    Inventor: Philippe Gabant
  • Patent number: 8877504
    Abstract: The present invention is related to a method for the selection of recombinant clones having integrated a gene of interest and a nucleotide sequence encoding a functional antidote protein to a toxic molecule, wherein said recombinant clones are the ones which survive following their integration into a host cell comprising in its genome a nucleotide sequence encoding said toxic molecule. The present invention is also related to a nucleic acid construct, a vector comprising said nucleic acid construct, a host cell and a cloning and/or sequencing kit for performing said method.
    Type: Grant
    Filed: June 17, 2013
    Date of Patent: November 4, 2014
    Assignee: Universite Libre de Bruxelles
    Inventors: Philippe Gabant, Laurence Van Melderen, Cedric Yves Szpirer
  • Publication number: 20130280810
    Abstract: The present invention is related to a method for the selection of recombinant clones having integrated a gene of interest and a nucleotide sequence encoding a functional antidote protein to a toxic molecule, wherein said recombinant clones are the ones which survive following their integration into a host cell comprising in its genome a nucleotide sequence encoding said toxic molecule. The present invention is also related to a nucleic acid construct, a vector comprising said nucleic acid construct, a host cell and a cloning and/or sequencing kit for performing said method.
    Type: Application
    Filed: June 17, 2013
    Publication date: October 24, 2013
    Inventors: Philippe Gabant, Laurence Van Melderen, Cedric Yves Szpirer
  • Patent number: 8470580
    Abstract: The present invention is related to a method for the selection of recombinant clones having integrated a gene of interest and a nucleotide sequence encoding a functional antidote protein to a toxic molecule, wherein said recombinant clones are the ones which survive following their integration into a host cell comprising in its genome a nucleotide sequence encoding said toxic molecule. The present invention is also related to a nucleic acid construct, a vector comprising said nucleic acid construct, a host cell and a cloning and/or sequencing kit for performing said method.
    Type: Grant
    Filed: February 22, 2002
    Date of Patent: June 25, 2013
    Assignee: Universite Libre de Bruxelles
    Inventors: Philippe Gabant, Laurence Van Melderen, Cédric Yves Szpirer
  • Publication number: 20130115658
    Abstract: The present invention is related to integrated method and tools to construct recombinant DNA molecules (to be used as DNA vaccine or gene therapy) without requiring the use of antibiotic(s) resistance gene(s) and without requiring the addition of one or more antibiotic(s) to the culture medium of cells submitted to this recombinant DNA method. The present invention allows to obtain the selection of recombinant host cell(s) transformed by a (exogenous) nucleic acid sequence of interest (extra-chromosomal vector containing the insert) and simultaneously stabilization (stable inheritance) of this (exogenous) nucleic acid sequence of interest into the transformed host cell(s) descendants (maintenance of the nucleic acid sequence of interest in the host cells population).
    Type: Application
    Filed: October 25, 2012
    Publication date: May 9, 2013
    Inventors: Cédric Szpirer, Michel C. Milinkovitch, Philippe Gabant